Clinical Trials Directory

Trials / Terminated

TerminatedNCT00272909

Efficacy of SUN N4057 in Subjects With Acute Ischemic Stroke and Measurable Penumbra on Magnetic Resonance Imaging (MRI)

A Phase IIb Randomized, Double-blind, Placebo-Controlled, Group-Sequential, Multicenter, Dose Finding Study of the Safety and Efficacy of SUN N4057 (Piclozotan) Administered for 72 Hours by Continuous Intravenous Infusion in Subjects With Acute Ischemic Stroke and Measurable Penumbra on MRI

Status
Terminated
Phase
Phase 2
Study type
Interventional
Enrollment
43 (actual)
Sponsor
Daiichi Sankyo · Industry
Sex
All
Age
18 Years – 85 Years
Healthy volunteers
Not accepted

Summary

This research study is designed to evaluate the safety, tolerability, and efficacy of SUN N4057 (piclozotan) in subjects with acute ischemic stroke within 9 hours of the onset of symptoms.

Detailed description

The primary objective of the study is to determine the efficacy of a 72 hour infusion of SUN N4057 (piclozotan) in subjects with clinical findings of an acute ischemic stroke and a magnetic resonance imaging (MRI) demonstrating a measurable penumbra (perfusion-weighted imaging \[PWI\] minus diffusion-weighted imaging \[DWI\] volume). Efficacy will be determined by comparing the proportion of subjects with no growth in stroke lesion volume as assessed by DWI at Screening to stroke lesion volume assessed by FLAIR (fluid-attenuated inversion recovery) on Day 28 in the piclozotan group versus the placebo group.

Conditions

Interventions

TypeNameDescription
DRUGpiclozotan low doseContinuous IV infusion over a period of up to 72 hours of piclozotan
DRUGplaceboContinuous IV infusion over a period of up to 72 hours of placebo.
DRUGpiclozotan high doseContinuous IV infusion over a period of up to 72 hours of piclozotan

Timeline

Start date
2004-09-01
Primary completion
2006-10-01
Completion
2007-01-01
First posted
2006-01-09
Last updated
2015-10-20

Locations

47 sites across 7 countries: United States, Belgium, Germany, Israel, Poland, South Africa, Spain

Source: ClinicalTrials.gov record NCT00272909. Inclusion in this directory is not an endorsement.